A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

October 6, 2023

Study Completion Date

November 27, 2023

Conditions
Anxiety Generalized
Interventions
DRUG

MM-120 (LSD D-Tartrate)

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

OTHER

Placebo

A substance that is designed to have no therapeutic value.

Trial Locations (22)

20850

Sunstone Therapies, Rockville

30030

iResearch Atlanta, Decatur

32801

CNS Healthcare - Orlando, Orlando

33319

Segal Trials, Lauderhill

44113

Lutheran Hospital - Cleveland Clinic, Cleveland

60640

Great Lakes Clinical Trials, Chicago

Uptown Research, Chicago

72211

Preferred Research Partners, Little Rock

77054

University of Texas Health Houston, Houston

78759

BioBehavioral Research of Austin, Austin

80209

Mountain View Clinical Research, Denver

80525

Wholeness Center, Fort Collins

84020

Cedar Clinical Research, Draper

84107

Cedar Clinical Research - Murray, Murray

90404

Pacific Neuroscience Institute, Santa Monica

92037

Kadima Neuropsychiatry Institute, La Jolla

92614

Irvine Center for Clinical Research, Irvine

01103

SISU, Springfield

02472

Adams Clinical, Watertown

08009

Hassman Research Institute, Berlin

08540

GMI - Princeton Medical Institute, Princeton

05091

Woodstock Research Center, Woodstock

All Listed Sponsors
lead

Mind Medicine, Inc.

INDUSTRY